Ovarian Cancer Treatment & Clinical Trials - Dana-Farber Cancer Institute

Ovarian Cancer Overview

Joan Janssen (left) and Ursula Matulonis, MD
If you or a loved one has ovarian cancer, the ovarian cancer team at the Susan F. Smith Center for Women's Cancers Gynecologic Oncology Program is here to help. The internationally recognized team of experts at the Susan F. Smith Center for Women's Cancers is dedicated to providing compassionate care and personalized diagnosis, treatment, and support all of our ovarian cancer patients and their loved ones.
Exceptional Care for Patients with Ovarian Cancer — You Have...
- A team of gynecologic oncology specialists who diagnose and treat hundreds of patients with ovarian cancer each year, and who are setting treatment guidelines for other physicians around the world
- Numerous clinical trials of emerging and novel treatments for ovarian cancer, some of which may not be available elsewhere
- Genetic testing and counseling and personalized early detection strategies for women and their families who have a hereditary risk of breast and ovarian and breast cancers
- Access to world-renowned pathologists who specialize in gynecologic cancer diagnosis
- Specialized care for people with sexual health or fertility concerns, and access to a wide array of support services and survivorship care
We Treat You, Not Just Your Cancer

We offer many programs to support our patients and their loved ones before, during, and after treatment, including:
Read our Insight blog for information and inspiration about ovarian cancer treatment at Dana-Farber.

New Patient Appointments
877-442-3324
Make Appointment Online

More Information
Becoming a Patient

As a new Dana-Farber patient, find answers to questions about your first visit: what to bring, how to find us, where to park, and how to prepare.

Support Services and Amenities

We offer a wide range of services, from financial planning to creative arts to spiritual counsel, to support our patients through their cancer experiences.

Support Services brochure

Breast and Ovarian Cancer Genetics and Prevention Program

If you or your doctor thinks you are at high risk of developing breast or ovarian cancer, the Cancer Genetics and Prevention Program, led by Judy Garber, MD, MPH, will create a personalized program to estimate your risk, and work with you and your clinical team to lower your risk as much as possible.
More information on ovarian cancer
Caregiving

Coping with Cancer

Health & Wellness

Nutrition & Diet

Risk & Prevention

Survivorship

Teaching Sheets

Treatments & Procedures

Video
News Releases
3/26/2019
Combination of PARP inhibitor and targeted therapy significantly outperforms PARP inhibitor alone in patients with chemotherapy-resistant ovarian cancer

Ovarian Cancer

News Releases
3/11/2019
Study of rare ovarian cancer sheds light on epigenetic cancer process

Ovarian Cancer

Insight Blog
1/25/2019
PARP Inhibitor Drugs May Now be Standard Part of Follow-up Therapy for Some Ovarian Cancer Patients

Ovarian Cancer
Gynecologic Cancer

News Releases
12/11/2018
Study shows PARP inhibitor drugs rouse immune system attack on some ovarian cancers

Research
Immunotherapy
Ovarian Cancer

Insight Blog
11/20/2018
Study Finds Source of PARP Inhibitor Drug Resistance

Ovarian Cancer

Insight Blog
10/15/2018
‘Organoids’ Could Aid Cancer Drug Selection

Immunotherapy
Susan F. Smith Center
Ovarian Cancer

Insight Blog
9/24/2018
It’s “Unprecedented”: After Two Recurrences, Ovarian Cancer Patient is “Living a Normal Life Again”

Patient Stories, Adult
Ovarian Cancer

Insight Blog
9/18/2018
After Two Relapses, Ovarian Cancer Patient is Thriving

Patient Stories, Adult
Susan F. Smith Center
Ovarian Cancer

News Releases
9/13/2018
Fast-growing organoid models of ovarian cancer could aid rapid drug treatment selection

Research
Ovarian Cancer

Ovarian Cancer

Ovarian Cancer Overview

Exceptional Care for Patients with Ovarian Cancer — You Have...

We Treat You, Not Just Your Cancer

More Information

More information on ovarian cancer

Combination of PARP inhibitor and targeted therapy significantly outperforms PARP inhibitor alone in patients with chemotherapy-resistant ovarian cancer

Study of rare ovarian cancer sheds light on epigenetic cancer process

PARP Inhibitor Drugs May Now be Standard Part of Follow-up Therapy for Some Ovarian Cancer Patients

Study shows PARP inhibitor drugs rouse immune system attack on some ovarian cancers

Study Finds Source of PARP Inhibitor Drug Resistance

‘Organoids’ Could Aid Cancer Drug Selection

It’s “Unprecedented”: After Two Recurrences, Ovarian Cancer Patient is “Living a Normal Life Again”

After Two Relapses, Ovarian Cancer Patient is Thriving

Fast-growing organoid models of ovarian cancer could aid rapid drug treatment selection